No Data
No Data
No Data
No Data
No Data
Express News | Kyverna Therapeutics To Attend The 2024 AAN Annual Meeting With Data On KYV-101 In Treatment Of Patients With Neurological Autoimmune Diseases
Moomoo 24/7Apr 11 17:16 ET
Kyverna Therapeutics to Attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients With Neurological Autoimmune Diseases
Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...
PR NewswireApr 11 17:01 ET
12 Health Care Stocks Moving In Monday's After-Market Session
GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in
BenzingaApr 1 16:31 ET
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The trea
PR NewswireMar 29 14:59 ET
Kyverna Therapeutics FY23 EPS $(89.61) Vs $(63.43) YoY
Financial Results for the Year Ended December 31, 2023For the year ended December 31, 2023, the company reported a net loss of $60.4 million, or a net loss per common share of $89.61, compared to a ne
BenzingaMar 26 16:20 ET
Kyverna Therapeutics 2023 R&D Expenses $49.9M >KYTX
Kyverna Therapeutics 2023 R&D Expenses $49.9M >KYTX
Dow JonesMar 26 16:06 ET
No Data
No Data